EICHORCondition: Atopic Dermatitis · Sponsor: LEO Pharma
Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD). Secondary objectives: To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo. Maintenance objective: To evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared to placebo for subjects achieving clinical response at Week 16.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Burke Pharmaceutical Research | Hot Springs, Arkansas, United States | — |
| California dermatology | Encinitas, California, United States | — |
| Advanced SkinCare Surgery & Med Center | Fullerton, California, United States | — |
| USC Department of Dermatology | Los Angeles, California, United States | — |
| Thiele Dermatology Specialists, Inc | Murrieta, California, United States | — |
| Island Dermatology | Newport Beach, California, United States | — |
| Therapeutics Clinical Research | San Diego, California, United States | — |
| San Luis Dermatology and Laser Clinic | San Luis Obispo, California, United States | — |
| Southern California Dermatology, Inc. | Santa Ana, California, United States | — |
| Olympian Clinical Research | Clearwater, Florida, United States | — |
| Spotlight Research Center, LLC | Miami, Florida, United States | — |
| Private Practice - Dr. Tory P. Sullivan | North Miami Beach, Florida, United States | — |
+ 103 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03160885